What is UCB Patient Assistance Program?
Through the UCB Patient Assistance Program, we provide some medications at no cost to eligible and qualified patients who are uninsured or underinsured who otherwise have no access to the UCB medicines prescribed by their physician.
Does AbbVie have a patient assistance program?
myAbbVie Assist. We believe that people who need our medicines should be able to get them. That's why myAbbVie Assist provides free AbbVie medicine to qualifying patients. If you have any questions, visit the FAQs or call us at 1-800-222-6885.
What is Allergan patient assistance program?
The Allergan Patient Assistance Program (PAP) provides Allergan medicines at no cost to eligible patients. If the patient qualifies, up to a twelve-month eligibility for the requested medication(s) or device(s) is approved for shipment to the patient's licensed prescriber for dispensing.
How do people afford Humira?
People without private insurance coverage may be able to get Humira at a reduced cost through Medicare or Medicaid. Medicare is a federal health insurance program for adults older than 65 and for individuals with certain disabilities.
How do you qualify for free eliquis?
You may be eligible for the Free 30-Day Trial Offer for ELIQUIS® (apixaban) if:You have not previously filled a prescription for ELIQUIS;You have a valid 30-day prescription for ELIQUIS;You are being treated with ELIQUIS for an FDA-approved indication that an HCP has planned for more than 35 days of treatment;More items...
What is AbbVie famous for?
AbbVie is a research-based biopharmaceutical company. It spun off of Abbott Laboratories in 2013. The company has had a successful start in its first five years in the industry. Its blockbuster drug Humira brought in billions.
Is AbbVie and Abbott the same company?
AbbVie was founded in 2013 when we became a separate company from Abbott. Our name represents a proud connection to that legacy.
Why did Abbott spin off AbbVie?
We talked a lot about the businesses evolving into different identities, and investors had different appetites. The spin off was a straight-forward way of changing. We let investors take the decision [of whether to hold or sell the new stock in AbbVie]. That was the rationale for the deal.